Bromsite 0.075% is commonly used to help with postoperative inflammation and to support the management of ocular pain in patients undergoing cataract surgery.

Managing Inflammation After Eye Surgery

This medication is generally used to address acute inflammation that may arise in the eye’s anterior segment following ocular procedures. It plays a role in supporting the management of inflammatory signs, which helps with mitigating swelling. It is considered relevant in clinical settings where heightened physiological responses need short-term, supportive assistance for symptom stabilization.

Managing Postoperative Ocular Pain and Discomfort

It is relevant in situations involving postoperative inflammation and the need for assistance with ocular pain management associated with the procedure. The medication may assist with symptoms related to physical discomfort during the recovery phase. This contributes to improved comfort during a period of heightened symptoms.

Quick Fact: Relief for Acute Postoperative Discomfort
Primary Use Context	Postoperative management following ocular procedures, typically cataract surgery.
Symptom Focus	Acute pain, discomfort, and swelling in the eye.
Therapeutic Role	Supportive symptomatic management during the recovery phase.

Regulatory References

1. DailyMed (NIH) labeling for Bromfenac Ophthalmic Solution

Eligibility Profile: Contraindications and Restrictions

Official regulatory information defines who is eligible to use Bromsite 0.075% based on absolute contraindications and conditional restrictions.

Absolute Non-Eligibility

The medication is strictly contraindicated for individuals with a known hypersensitivity or allergic reaction to any ingredient in the formulation. This exclusion extends to those with documented cross-sensitivity to acetylsalicylic acid or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Use is strictly avoided during the third trimester of pregnancy and must be immediately discontinued upon evidence of corneal epithelial breakdown.

Age and Conditional Use

Population Group	Eligibility Status	Limitation/Restriction
Adults (18+ years)	Approved for use	Use is established.
Pediatrics (<18 years)	Use is Not Established	Safety and efficacy have not been established by regulators.
Nursing Mothers	Restricted Use	Caution should be exercised when administered.
Comorbid Conditions	Caution Required	Patients with diabetes mellitus, rheumatoid arthritis, or known bleeding tendencies.

The medicine is approved primarily for adults. Eligibility requires special consideration and caution in patients with specific systemic conditions or ocular risk factors. It must also not be administered while wearing contact lenses.

Bromsite 0.075% is an ophthalmic nonsteroidal anti-inflammatory drug (NSAID) whose official interaction profile is structured around local pharmacodynamic effects and mandatory administration rules, given its minimal systemic absorption. No specific combinations are formally contraindicated due to interaction risks, and official labels do not detail systemic metabolic or transporter-based interactions.

Pharmacodynamic Interaction Patterns

Interacting Product Category	Official Interaction Outcome
Topical Corticosteroids	Co-administration may increase the potential for slow or delayed healing.
Medications Which May Prolong Bleeding Time	Potential for increased bleeding time of ocular tissue, particularly in conjunction with ocular surgery.

Co-administration with other substances that may prolong bleeding time, such as oral anticoagulants or platelet aggregation inhibitors, carries an explicit caution due to the NSAID class's interference with platelet aggregation. Furthermore, the drug’s classification as a phenylacetic acid derivative establishes the potential for cross-sensitivity to acetylsalicylic acid and other nonsteroidal anti-inflammatory agents.

Timing and Separation Requirements

Official regulatory guidance mandates a specific administrative separation when using this product with other topical ophthalmic medications. Drops, including those for glaucoma (e.g., alpha-agonists, beta-blockers, carbonic anhydrase inhibitors) or dilation (e.g., cycloplegics, mydriatics), must be administered at least five minutes apart from Bromsite 0.075%.

Bromsite 0.075% (bromfenac ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) that intervenes in key biochemical pathways responsible for the production of lipid mediators within ocular tissues.

---

Inhibition of Prostaglandin Synthesis

This mechanism involves the COX enzymes, specifically inhibiting both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). By blocking these enzymes, Bromsite suppresses the initial molecular steps that convert arachidonic acid into prostaglandins, which are powerful lipid mediators.

---

Regulation of Inflammatory Cascades

The resulting reduction in prostaglandin concentration modifies the signaling sequences that drive inflammatory processes. Prostaglandins normally promote responses like vasodilation, increased vascular permeability, and the migration of immune cells (leukocytes). This action modulates downstream signaling within targeted ocular pathways.

---

Enhanced Ocular Tissue Penetration

The unique chemical structure of bromfenac, which includes a bromine atom, enhances the molecule's lipophilicity. This structural feature facilitates the molecule's diffusion across corneal layers to reach intraocular tissues, influencing its localized concentration.

How to Use Bromsite 0.075%

Bromsite 0.075% is an ophthalmic solution for topical administration, intended to be applied directly to the affected eye(s) as a drop. The dosing regimen is structured around the timing of cataract surgery. The standard regimen for adult patients is the application of one drop of the 0.075% solution twice daily, administered in the morning and evening.

This medication follows a specific, time-bound usage pattern. Administration begins one day prior to the scheduled surgery, continues on the day of the procedure, and is then maintained for a total of 14 days postsurgery. This defines a precise 16-day treatment course designed for the perioperative period. The solution is used consistently at this twice-daily frequency without requiring preparation, as it is supplied as a ready-to-use formulation.

Specific administration constraints must be observed for proper use. A key procedural restriction is that contact lenses must not be worn throughout the entire treatment period. If other topical ophthalmic drops are part of the therapeutic plan, there must be a minimum interval of 5 minutes between applications to ensure proper drug retention and absorption. The safety and effectiveness of the 0.075% ophthalmic solution have not been established for use in pediatric patients under the age of 18.

Evidence for Use in Managing Post-Cataract Inflammation and Pain

Research examined the use of Bromsite 0.075% in the context of postsurgical recovery following routine cataract surgery. The core clinical evidence was studied by evaluating two key outcomes related to physical discomfort and inflammatory or irritative states. These studies were designed as randomized, controlled clinical trials (RCTs), where the medication was compared against a vehicle (the eye drop base without the active ingredient).

In these controlled studies, researchers monitored physiological strain by looking at the clearance of inflammatory cells in the front of the eye. They also examined patient-reported outcomes related to physical discomfort (pain). The findings describe patterns observed in the trials where a higher proportion of participants in the study group met the study endpoint of complete clearance of inflammatory cells and met the study endpoint of being pain-free at the observation time point (around two weeks after the procedure) compared to those receiving the vehicle. The research provides context for short-term symptom patterns during the recovery phase.

---

Follow-up Duration and Research Gaps

The core evidence collected for this formulation was primarily conducted during the acute recovery phase following surgery. Follow-up durations were limited, with the main outcomes being assessed up to roughly 15 to 29 days after the cataract procedure. Long-term effects are not fully established, and evidence remains limited for outcomes occurring many months or years after use.

Studies also researched the drug's absorption and presence in eye tissues (pharmacokinetic studies), which provides context for the short-term distribution and delivery of the medication. The clinical trials primarily evaluated a population of adult patients (ge 18 years). Data for certain groups remain insufficient, such as pediatric patients (children under 18 years of age) or those undergoing complex ocular procedures. Comparative evidence is lacking for how this specific formulation was observed in conditions outside the surgical recovery setting.

Key Studies & References

1. DailyMed Labeling for Bromfenac Ophthalmic Solution
2. MedlinePlus Drug Information on Bromfenac Ophthalmic

Common questions about Bromsite 0.075% (FAQ)

---

Q: Why is the concentration of the drop 0.075% instead of 0.09%?

Bromsite is a specific formulation of the active ingredient bromfenac that uses a unique drug delivery system, known as DuraSite®. Non-clinical studies suggest that this system results in higher concentrations of the medication reaching eye tissues. This 0.075% formulation achieved comparable or higher internal drug levels compared to the older 0.09% bromfenac formulation.

---

Q: What are the possible risks of using Bromsite if I have dry eyes?

Official safety information indicates that patients who have existing ocular surface diseases, which includes conditions like dry eye syndrome, may face an increased risk. This risk is associated with the potential for more severe corneal adverse events when using this class of topical medication (NSAIDs).

---

Q: Can Bromsite be used in both eyes if only one eye had surgery?

The official labeling indicates that the recommended dosing is one drop to the affected eye twice daily. The approved use of the drug is specifically tied to managing inflammation and pain in the eye undergoing cataract surgery.

---

Q: What should I look out for that would indicate a serious side effect?

Official labeling specifies that serious corneal adverse events can include conditions such as corneal erosion, corneal thinning, or corneal ulceration. If signs of corneal epithelial breakdown are observed, the labeling states that discontinuation of the medication is required.

---

Q: How long does the effect of one drop of Bromsite last?

The prescribing information specifies a twice-daily administration schedule, once in the morning and once in the evening. This schedule allows for the maintenance of drug levels in the eye based on regulatory review of the drug's half-life.

---

Q: What should I do if I miss a dose of Bromsite?

Patient instructions describe that if a dose is missed, it can be administered as soon as it is recalled, unless it is nearly time for the next scheduled dose. In that situation, the instruction is to skip the missed dose and resume the normal schedule. The information further specifies that doses must not be doubled.

---

Q: Can older adults use Bromsite 0.075% safely?

According to the official FDA labeling regarding geriatric use, studies did not find evidence that the effectiveness or safety profiles of Bromsite differed in patients 65 years of age and older compared to younger adult patients.

---

Q: What are the ingredients besides the active medication?

The official product description indicates that the solution is formulated with the DuraSite® drug delivery system. It also contains the common preservative benzalkonium chloride (BAK) as one of the inactive components.

---

Q: Are there studies on how Bromsite affects visual outcomes?

Clinical studies conducted to support the drug's approval focused on two primary clinical endpoints: the resolution of postsurgical inflammation (measured by cell clearance in the eye) and the prevention of ocular pain. These were the main goals evaluated in the trials.

Storage and Disposal Requirements

Bromsite 0.075% must be stored in a closed container at room temperature, which is officially defined as not exceeding 25 C. The product is required to be kept away from heat, moisture, and direct light, and must be protected from freezing. To maintain the sterility of the ophthalmic solution, the container must be kept tightly closed at all times.

After the initial opening of the bottle, the medicine has an in-use stability period and must be used within 32 days.

For safety, the product must be stored out of the reach of children. Unused or expired medicine should not be kept; the official instruction is to ask a healthcare professional how any unused medicine should be disposed of.